490 related articles for article (PubMed ID: 32961897)
1. Induction of the Antiviral Immune Response and Its Circumvention by Coronaviruses.
Liu P; Hong Y; Yang B; Shrestha P; Sajjad N; Chen JL
Viruses; 2020 Sep; 12(9):. PubMed ID: 32961897
[TBL] [Abstract][Full Text] [Related]
2. Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past.
Shah VK; Firmal P; Alam A; Ganguly D; Chattopadhyay S
Front Immunol; 2020; 11():1949. PubMed ID: 32849654
[TBL] [Abstract][Full Text] [Related]
3. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.
Azkur AK; Akdis M; Azkur D; Sokolowska M; van de Veen W; Brüggen MC; O'Mahony L; Gao Y; Nadeau K; Akdis CA
Allergy; 2020 Jul; 75(7):1564-1581. PubMed ID: 32396996
[TBL] [Abstract][Full Text] [Related]
4. A molecular arms race between host innate antiviral response and emerging human coronaviruses.
Wong LY; Lui PY; Jin DY
Virol Sin; 2016 Feb; 31(1):12-23. PubMed ID: 26786772
[TBL] [Abstract][Full Text] [Related]
5. Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19).
Yuan S; Chan CC; Chik KK; Tsang JO; Liang R; Cao J; Tang K; Cai JP; Ye ZW; Yin F; To KK; Chu H; Jin DY; Hung IF; Yuen KY; Chan JF
Viruses; 2020 Jun; 12(6):. PubMed ID: 32532085
[TBL] [Abstract][Full Text] [Related]
6. Surviving COVID-19: A disease tolerance perspective.
Ayres JS
Sci Adv; 2020 May; 6(18):eabc1518. PubMed ID: 32494691
[No Abstract] [Full Text] [Related]
7. Type I and Type III Interferons - Induction, Signaling, Evasion, and Application to Combat COVID-19.
Park A; Iwasaki A
Cell Host Microbe; 2020 Jun; 27(6):870-878. PubMed ID: 32464097
[TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2-A Tough Opponent for the Immune System.
Nasab MG; Saghazadeh A; Rezaei N
Arch Med Res; 2020 Aug; 51(6):589-592. PubMed ID: 32532524
[TBL] [Abstract][Full Text] [Related]
9. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR
Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711
[TBL] [Abstract][Full Text] [Related]
10. LY6E Restricts Entry of Human Coronaviruses, Including Currently Pandemic SARS-CoV-2.
Zhao X; Zheng S; Chen D; Zheng M; Li X; Li G; Lin H; Chang J; Zeng H; Guo JT
J Virol; 2020 Aug; 94(18):. PubMed ID: 32641482
[TBL] [Abstract][Full Text] [Related]
11. Viral Evasion of the Complement System and Its Importance for Vaccines and Therapeutics.
Mellors J; Tipton T; Longet S; Carroll M
Front Immunol; 2020; 11():1450. PubMed ID: 32733480
[TBL] [Abstract][Full Text] [Related]
12. A tug-of-war between severe acute respiratory syndrome coronavirus 2 and host antiviral defence: lessons from other pathogenic viruses.
Fung SY; Yuen KS; Ye ZW; Chan CP; Jin DY
Emerg Microbes Infect; 2020; 9(1):558-570. PubMed ID: 32172672
[TBL] [Abstract][Full Text] [Related]
13. Innate Immune Responses to Highly Pathogenic Coronaviruses and Other Significant Respiratory Viral Infections.
Ahmed-Hassan H; Sisson B; Shukla RK; Wijewantha Y; Funderburg NT; Li Z; Hayes D; Demberg T; Liyanage NPM
Front Immunol; 2020; 11():1979. PubMed ID: 32973803
[TBL] [Abstract][Full Text] [Related]
14. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.
Keam S; Megawati D; Patel SK; Tiwari R; Dhama K; Harapan H
Rev Med Virol; 2020 Sep; 30(5):e2123. PubMed ID: 32648313
[TBL] [Abstract][Full Text] [Related]
15. Mitigating Coronavirus Induced Dysfunctional Immunity for At-Risk Populations in COVID-19: Trained Immunity, BCG and "New Old Friends".
Kleen TO; Galdon AA; MacDonald AS; Dalgleish AG
Front Immunol; 2020; 11():2059. PubMed ID: 33013871
[TBL] [Abstract][Full Text] [Related]
16. Innate immune evasion by SARS-CoV-2: Comparison with SARS-CoV.
Bouayad A
Rev Med Virol; 2020 Nov; 30(6):1-9. PubMed ID: 32734714
[TBL] [Abstract][Full Text] [Related]
17. In vivo antiviral host transcriptional response to SARS-CoV-2 by viral load, sex, and age.
Lieberman NAP; Peddu V; Xie H; Shrestha L; Huang ML; Mears MC; Cajimat MN; Bente DA; Shi PY; Bovier F; Roychoudhury P; Jerome KR; Moscona A; Porotto M; Greninger AL
PLoS Biol; 2020 Sep; 18(9):e3000849. PubMed ID: 32898168
[TBL] [Abstract][Full Text] [Related]
18. Interferon Control of Human Coronavirus Infection and Viral Evasion: Mechanistic Insights and Implications for Antiviral Drug and Vaccine Development.
Zhao X; Chen D; Li X; Griffith L; Chang J; An P; Guo JT
J Mol Biol; 2022 Mar; 434(6):167438. PubMed ID: 34990653
[TBL] [Abstract][Full Text] [Related]
19. Daily Viral Kinetics and Innate and Adaptive Immune Response Assessment in COVID-19: a Case Series.
Vetter P; Eberhardt CS; Meyer B; Martinez Murillo PA; Torriani G; Pigny F; Lemeille S; Cordey S; Laubscher F; Vu DL; Calame A; Schibler M; Jacquerioz F; Blanchard-Rohner G; Siegrist CA; Kaiser L; Didierlaurent AM; Eckerle I
mSphere; 2020 Nov; 5(6):. PubMed ID: 33177214
[TBL] [Abstract][Full Text] [Related]
20. What's Sex Got to Do With COVID-19? Gender-Based Differences in the Host Immune Response to Coronaviruses.
Gadi N; Wu SC; Spihlman AP; Moulton VR
Front Immunol; 2020; 11():2147. PubMed ID: 32983176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
